BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001) (NCT07193511)
A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-103, a Nectin4/Trop2 ADC, as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This study, the first clinical trial of AVZO-103, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-103 when administered intravenously as a monotherapy and in combination therapy to patients with locally advanced or metastatic urothelial cancer or other solid tumors.
Who can join: Review the eligibility criteria below.
Location: Avenzo Therapeutics Recruiting Site — San Francisco, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (14 Sites)
- Avenzo Therapeutics Recruiting Site — San Francisco, California
- Avenzo Therapeutics Recruiting Site — Aurora, Colorado
- Avenzo Therapeutics Recruiting Site — New Haven, Connecticut
- Avenzo Therapeutics Recruiting Site — Orlando, Florida
- Avenzo Therapeutics Recruiting Site — Tampa, Florida
- Avenzo Therapeutics Recruiting Site — Boston, Massachusetts
- Avenzo Therapeutics Recruiting Site — New York, New York
- Avenzo Therapeutics Recruiting Site — Chapel Hill, North Carolina
- Avenzo Therapeutics Recruiting Site — Cleveland, Ohio
- Avenzo Therapeutics Recruiting Site — Myrtle Beach, South Carolina
- Avenzo Therapeutics Recruiting Site — Nashville, Tennessee
- Avenzo Therapeutics Recruiting Site — Austin, Texas
- Avenzo Therapeutics Recruiting Site — Houston, Texas
- Avenzo Therapeutics Recruiting Site — Irving, Texas
📞 Contact the Study Coordinator
Phone: (858) 239-2944
Email: ClinicalTrials@avenzotx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumor Cancer
- Impact of Duffy-null Associated Neutropenia on Chemotherapy Dosing — Detroit, Michigan
- A Study of a Distress Screening and Referral Program in People With Recently Diagnosed Cancer — New York, New York
- Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors — Santa Monica, California
- AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) — Gilbert, Arizona
Explore by condition: All Solid Tumor Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.